Breast cancer research: lessons learnt from the past will shape the future
In her key lecture, the 2024 ESMO Breast Cancer Awardee Prof. Hope S. Rugo reflects on the current challenges in the field
Atezolizumab does not improve prognosis in early relapsing advanced triple-negative breast cancer
However, a higher objective response rate with atezolizumab was reported in the IMpassion132 trial suggesting that at least some patients could benefit from it
New insights into the evolutionary pattern of breast cancer
A more detailed picture of breast cancer establishment may facilitate prevention and detection in women at high risk
Making personalised precision medicine a reality for early breast cancer
Individualised assessment of initial response to therapy may pave the way for chemotherapy-sparing treatment, but it requires that multidisciplinary teams adapt their current practices
The growing role of AI in breast cancer
The rapidly increasing integration of AI into many aspects of breast cancer management calls for urgent definition of expected levels of evidence and bespoke regulatory and reimbursement processes
Fuzuloparib prolongs progression-free survival in HER2 negative metastatic breast cancer
A benefit was observed in women with germline BRCA1/2 mutations when treated with the PARP inhibitor alone or in combination with apatinib
Breast cancer: is the future of PARP inhibitors bright?
Benefits of these targeted agents are not limited to tumours with germline BRCA1/2 mutations, but many questions remain to be answered
Early breast cancer: higher quality of life reported with a personalised follow-up
A nurse-led follow-up strategy including self-management interventions, use of patient-reported outcomes and phone consultations also resulted in lower fear of recurrence, anxiety and depression
Most women report poor sexual health after a diagnosis of breast cancer
However, patients’ sexual concerns are often unaddressed in oncology, a study suggests
Long-term data confirm a survival benefit with adjuvant anthracycline-taxane-based chemotherapy in early breast cancer
Updated analysis of the ABC trials favors anthracycline-based regimens in terms of IDFS and RFI, but no OS, when compared to taxane-based chemotherapy